the genomic characterization of primary and metastatic her2-low breast cancers
Published 1 year ago • 54 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
1:45
the comprehensive genomic characterization of her2-low breast cancer
-
1:26
genomic and transcriptomic landscape of her2-low breast cancer
-
0:45
the evolution of her2-low breast cancer from primary to recurrence
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
2:14
clinical and molecular characteristics of her2-low/zero early stage triple-negative breast cancer
-
1:09
the exciting new field of her2-low breast cancer
-
1:10
the evolution of her2-low-positive breast cancer as a clinical subtype
-
1:36
is her2-low a distinct subtype of breast cancer?
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
0:56
remaining questions on the management of her2-low breast cancer
-
6:51
adcs for her2 and her2-low breast cancer
-
1:33
questions remaining in the field of her2-low breast cancer
-
0:46
biological behaviour of her2-low bc is dependent on hr expression
-
11:25
podcast 293: her2-“low” breast cancer and its reponse to an antibody-drug conjugate
-
1:49
early breast cancer: do we need chemotherapy in low genomic/high clinical risk (er /her2-)?
-
1:05
efficacy of trastuzumab deruxtecan in her2-low metastatic breast cancer
-
2:05
perelisa: overexpression of 13 genes associated with endocrine sensitivity in hr /her2 bc
-
0:53
tuxedo-1: t-dxd for patients with her2-positive breast cancer and brain metastasis
-
0:56
her2-low status as a therapeutic target in advanced breast cancer